Cargando…

Corrigendum to “Retrospective Observational Study on Rebamipide Ophthalmic Suspension on Quality of Life of Dry Eye Disease Patients”

Detalles Bibliográficos
Autores principales:	Sakane, Yuri, Yamaguchi, Masahiko, Shiraishi, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519998/ https://www.ncbi.nlm.nih.gov/pubmed/33014444 http://dx.doi.org/10.1155/2020/8486704

Ejemplares similares

Retrospective Observational Study on Rebamipide Ophthalmic Suspension on Quality of Life of Dry Eye Disease Patients
por: Sakane, Yuri, et al.
Publicado: (2019)

Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
por: Kashima, Tomoyuki, et al.
Publicado: (2014)

Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye
por: Ueda, Kaori, et al.
Publicado: (2015)

Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre
por: Jain, Kalpna, et al.
Publicado: (2023)

Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes
por: Shrivastava, Saurabh, et al.
Publicado: (2018)

Assessment of mucin-related gene alterations following treatment with rebamipide ophthalmic suspension in Sjögren’s syndrome-associated dry eyes
por: Shoji, Jun, et al.
Publicado: (2020)

The Efficacy and Safety of Rebamipide Ophthalmic Suspension (OPC-12759) in Patients with Dry Eye Disease: A Systematic Review of Randomized Controlled Trials
por: Ballesteros-Sánchez, Antonio, et al.
Publicado: (2023)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients [Corrigendum]
Publicado: (2013)

Evaluation of dacryocystorhinostomy using optical coherence tomography and rebamipide ophthalmic suspension
por: Fujimoto, Masahiro, et al.
Publicado: (2014)

Efficacy and Safety of Retinol Palmitate Ophthalmic Solution in the Treatment of Dry Eye: A Japanese Phase II Clinical Trial [Corrigendum]
Publicado: (2021)

Alkali Burn Treated with 2% Rebamipide Ophthalmic Suspension: A Case Report
por: Sasaki, Hidenori, et al.
Publicado: (2014)

Corrigendum to “The Role of Medications in Causing Dry Eye”
por: Fraunfelder, Frederick T., et al.
Publicado: (2019)

Rebamipide ophthalmic solution modulates the ratio of T helper cell 17/regulatory T cells in dry eye disease mice
por: Fu, Rongrong, et al.
Publicado: (2019)

The Effects of Rebamipide 2% Ophthalmic Solution Application on Murine Subbasal Corneal Nerves After Environmental Dry Eye Stress
por: Simsek, Cem, et al.
Publicado: (2019)

Case Report: A Rare Orbital Abscess Caused by Dacryocystitis After Administration of Rebamipide Ophthalmic Suspension
por: Imamura, Hitoshi, et al.
Publicado: (2021)

Efficacy of Rebamipide Instillation for Contact Lens Discomfort With Dry Eye
por: Igarashi, Tsutomu, et al.
Publicado: (2018)

How Can We Best Diagnose Severity Levels of Dry Eye Disease: Current Perspectives [Corrigendum]
Publicado: (2023)

The Effect of Rebamipide on Refractive Accuracy of Cataract Surgery in Patients with Dry Eye
por: Teshigawara, Takeshi, et al.
Publicado: (2022)

Corrigendum to “Pulsed Radiofrequency of the Trigeminal Ganglion for Treating Postherpetic Neuralgia of the Ophthalmic Branch”
por: Liu, Dong-Yang, et al.
Publicado: (2021)

Long-term Rebamipide and Diquafosol in Two Cases of Immune-Mediated Dry Eye
por: Yamane, Mio, et al.
Publicado: (2015)

Corrigendum to: Drying banana seeds for ex situ conservation
por: Kallow, Simon, et al.
Publicado: (2022)

Success of patient training in improving proficiency of eyedrop administration among various ophthalmic patient populations [Corrigendum]
Publicado: (2017)

Novel Sustained-Release Drug Delivery System for Dry Eye Therapy by Rebamipide Nanoparticles
por: Nagai, Noriaki, et al.
Publicado: (2020)

Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
por: Venkateswaran, Nandini, et al.
Publicado: (2022)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Publicado: (2013)

Corrigendum to “Relationship between the Direction of Ophthalmic Artery Blood Flow and Ocular Microcirculation before and after Carotid Artery Stenting”
por: Ishii, Masashi, et al.
Publicado: (2017)

Corrigendum to “Ophthalmic considerations in patients with pfeiffer syndrome.” [Am. J. Ophthalmol. Case Reports (2) 2016 1–3]
por: Clark, Jeremy D., et al.
Publicado: (2017)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
Publicado: (2018)

Corrigendum to "LifeWatch observatory data: phytoplankton observations in the Belgian Part of the North Sea"
por: Amadei Martínez, Luz, et al.
Publicado: (2022)

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Publicado: (2019)

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Publicado: (2018)

Corrigendum: Increased Melanoma-Associated Antigen C2 Expression Affords Resistance to Apoptotic Deathin Suspension-Cultured Tumor Cells
por: Park, Doyeon, et al.
Publicado: (2022)

Corrigendum to “Utility of Experimental Design in Pre-Column Derivatization for the Analysis of Tobramycin by HPLC—Fluorescence Detection: Application to Ophthalmic Solution and Human Plasma”
por: El-Zaher, Asmaa A, et al.
Publicado: (2014)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Publicado: (2018)

Analysis of Risk Factors for Revitrectomy in Eyes with Diabetic Vitreous Hemorrhage [Corrigendum]
Publicado: (2023)

The Efficacy of 2% Topical Rebamipide on Conjunctival Squamous Metaplasia and Goblet Cell Density in Dry Eye Disease
por: Simsek, Cem, et al.
Publicado: (2019)

Corrigendum to Home food insecurity during the suspension of classes in Brazilian public schools due to the COVID-19 pandemic [Nutrition 93 (2022) 111448]
por: Rodrigues, Erica Costa, et al.
Publicado: (2022)

Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye
por: Labetoulle, M, et al.
Publicado: (2017)

Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes
por: Hayashi, Yusuke, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lprggaalsrt74d3o23pg92v7gd